Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy

References

• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl 1):3–63
   Google Scholar
• Grady D, Rubin SM, Petitti DB, et al Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–1037
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–613
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53:605–619
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–1477
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Ylikorkala O. Hormone therapy and cardiovascular disease – still much to be learnt. Gynecol Endocrinol 2005;20:116–120
   PubMed Web of Science ®Google Scholar
• van der Schouw YT, Grobbee DE. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. Eur Heart J 2005;26:1358–1361
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Stovall DW. Is there an association between vasomotor symptoms and both low bone density and cardiovascular risk? Menopause 2009;16:219–223
   PubMed Web of Science ®Google Scholar
• Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study. Circulation 2008;118:1234–1240
   PubMed Web of Science ®Google Scholar
• Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause 2009;16:639–643
   PubMed Web of Science ®Google Scholar
• Svartberg J, von Muhlen D, Kritz-Silverstein D, Barrett-Connor E. Vasomotor symptoms and mortality: the Rancho Bernardo Study. Menopause 2009;16:888–891
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–843
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026–2033
   PubMed Web of Science ®Google Scholar
• Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88:2470–2478
   PubMed Web of Science ®Google Scholar
• Chan DC, Watts GF. Apolipoproteins as markers and managers of coronary risk. QJM 2006;99:277–287
   PubMed Web of Science ®Google Scholar
• Sutton-Tyrrell K, Wildman RP, Matthews KA, et al Sex hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women's Health Across the Nation (SWAN). Circulation 2005;111:1242–1249
   PubMed Web of Science ®Google Scholar
• Evangelista O, McLaughlin MA. Review of cardiovascular risk factors in women. Gender Med 2009;6:17–36
   PubMed Web of Science ®Google Scholar
• Leal M, Diaz J, Serrano E, Abellan J, Carbonell LF. Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes. Obstet Gynecol 2000;95:804–809
   PubMed Web of Science ®Google Scholar
• Gast GC, Grobbee DE, Pop VJ, et al Menopausal complaints are associated with cardiovascular risk factors. Hypertension 2008;51:1492–1498
   PubMed Web of Science ®Google Scholar
• Tuomikoski P, Mikkola TS, Hämäläinen E, Tikkanen MJ, Turpeinen U, Ylikorkala O. Biochemical markers for cardiovascular disease in recently postmenopausal women with and without hot flashes. Menopause 2009;17:145–151
   Web of Science ®Google Scholar
• Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 2001;75:898–915
   PubMed Web of Science ®Google Scholar
• Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 2008;90:642–672
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726–731
   PubMed Web of Science ®Google Scholar
• Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280–4290
   PubMed Web of Science ®Google Scholar
• Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:120–131
   PubMed Web of Science ®Google Scholar
• Tuomikoski P, Ebert P, Groop PH, et al Effect of hot flushes on vascular function: a randomized controlled trial. Obstet Gynecol 2009;114:777–785
   PubMed Web of Science ®Google Scholar
• Koh KK, Sakuma I. Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials? Arterioscler Thromb Vasc Biol 2004;24:1171–1179
   PubMed Web of Science ®Google Scholar
• Kuhl H, Stevenson J. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits – an attempt to interpret the Women's Health Initiative results. Gynecol Endocrinol 2006;22:303–317
   PubMed Web of Science ®Google Scholar
• Ropponen A, Aittomäki K, Tikkanen MJ, Ylikorkala O. Levels of serum C-reactive protein during oral and transdermal estradiol in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy. J Clin Endocrinol Metab 2005;90:142–146
   PubMed Web of Science ®Google Scholar
• Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002;105:1436–1439
   PubMed Web of Science ®Google Scholar
• Sumino H, Ichikawa S, Kasama S, et al Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006;189:436–442
   PubMed Web of Science ®Google Scholar
• Vrablik M, Fait T, Kovar J, Poledne R, Ceska R. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. Metabolism 2008;57:1088–1092
   PubMed Web of Science ®Google Scholar
• Anderson PW, Cox DA, Sashegyi A, Paul S, Silfen SL, Walsh BW. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas 2001;39:71–77
   PubMed Web of Science ®Google Scholar
• Sowers MR, Randolph J Jr, Jannausch M, Lasley B, Jackson E, McConnell D. Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife: implications for the ‘timing hypothesis’. Arch Intern Med 2008;168:2146–2153
   PubMed Web of Science ®Google Scholar